Full-Time

Technical Threat Investigator

Threat Intel Engineering

OpenAI

OpenAI

5,001-10,000 employees

Develops safe AI models and tools

Compensation Overview

$234k - $385k/yr

San Francisco, CA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Regular in-person engagement with SF HQ; relocation assistance available to SF.

Category
IT & Security (1)
Requirements
  • Experience in threat intelligence, incident response, offensive security, or a closely related field.
  • Solid experience investigating sophisticated threat actors, including model misuse, platform abuse, or other adversarial activity in complex environments.
  • A strong understanding of adversary behavior, infrastructure, and tradecraft, and the ability to apply that understanding to proactive investigations.
  • Demonstrated ability to independently drive deep technical investigations from ambiguous signals through to clear, actionable findings.
  • Experience using AI to extend or accelerate investigative workflows.
  • Strong scripting ability and comfort building lightweight automation, investigative tooling, or workflows that improve scale and repeatability.
  • Strong ability to leverage telemetry from diverse systems and vendors to drive investigations, including directly querying, extracting, and stitching together data where needed.
  • Strong written and verbal communication skills, especially the ability to translate technical investigations into high-signal outputs for diverse stakeholders.
  • Comfort operating independently in ambiguous, fast-moving problem spaces with minimal oversight.
Responsibilities
  • Conduct deep, end-to-end investigations into sophisticated threat actors interacting with OpenAI’s models, products, and broader ecosystem.
  • Think like an adversary — model attacker behavior, anticipate misuse patterns, and proactively hunt for, identify, and disrupt malicious activity.
  • Leverage internal telemetry, OSINT, vendor data, and in-house safety systems to produce high-confidence findings on adversarial use of our models in cyber operations, platform abuse, and threats targeting OpenAI.
  • Translate investigative findings into concrete improvements across detection, enforcement, intel, and safety pipelines.
  • Build tooling, scripts, automations, and agentic workflows that scale investigative throughput and reduce manual effort.
  • Prototype solutions in ambiguous and emerging problem spaces, including new product surfaces, novel attacker behaviors, and areas where existing coverage may be limited.
  • Partner closely with teams across Security, Safety Systems, Product Policy, and Integrity to operationalize findings and drive meaningful outcomes.
  • Produce clear, high-signal written outputs and recommendations that inform decision-making across technical and executive stakeholders.

OpenAI conducts AI research and deployment to build advanced AI models and tools that help people automate tasks, be more creative, and make better decisions. Its products include ChatGPT, a conversational AI that can write, code, tutor, and assist in interactive tasks, and Sora, which can generate videos from text prompts. OpenAI’s models typically run through cloud-based services and subscriptions, with licensing and partnerships for broader use. The company operates a capped-profit model to balance generating revenue with ensuring safety, ethics, and long-term societal benefits. Its approach emphasizes safety, responsible deployment, and collaboration with researchers, governments, and institutions. The goal is to ensure artificial general intelligence, when it arrives, benefits all of humanity and minimizes risks.

Company Size

5,001-10,000

Company Stage

Late Stage VC

Total Funding

$196B

Headquarters

San Francisco, California

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • SoftBank pledges $30B more in 2026, valuing OpenAI at $850B with $25B annualized revenue.
  • University of Michigan's $20M investment yields $2B, signaling strong early investor returns.
  • TPG joint venture with billions in PE funding boosts corporate AI adoption rates.

What critics are saying

  • Microsoft divests after $100B spend by June 2026, funding Anthropic and xAI instead.
  • Doubled GPT-5.5 API prices to $5/$30 per million tokens slash 5% subscriber conversions.
  • Europe bans GPT-5.5-Cyber for non-partners post-Mythos, blocking Trusted Access expansion.

What makes OpenAI unique

  • Trusted Access for Cyber grants vetted users GPT-5.4-Cyber for binary reverse engineering.
  • Daybreak platform automates threat prioritization, patching, and fix verification in software development.
  • Deployment Company with 150 Tomoro engineers accelerates enterprise AI integration via partnerships.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at OpenAI who can refer or advise you

Benefits

Health insurance

Dental and vision insurance

Flexible spending account for healthcare and dependent care

Mental healthcare service

Fertility treatment coverage

401(k) with generous matching

20-week paid parental leave

Life insurance (complimentary)

AD&D insurance (complimentary)

Short-term/long-term disability insurance (complimentary)

Optional buy-up life insurance

Flexible work hours and unlimited paid time off (we encourage 4+ weeks per year)

Annual learning & development stipend

Regular team happy hours and outings

Daily catered lunch and dinner

Travel to domestic conferences

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

3%

2 year growth

2%
Daring Fireball
May 8th, 2026
Y Combinator’s Stake in OpenAI

The fact that Paul Graham personally has billions of dollars at stake with OpenAI doesn’t mean that his public opinion on Sam Altman’s trustworthiness and leadership is invalid. But it certainly seems like the sort of thing that ought to be disclosed when quoting Graham as an Altman character reference.

Bloomberg L.P.
Apr 21st, 2026
OpenAI launches ChatGPT Images 2.0 with improved chart and diagram creation

OpenAI is releasing ChatGPT Images 2.0, an updated AI image-generating software designed to create accurate charts and scientific diagrams. The company aims to make its technology more appealing to professionals. Rolling out Tuesday through ChatGPT and Codex AI coding assistant, the new model improves instruction-following and detail incorporation when generating images. It can produce visuals across multiple styles and render text in various languages. The update represents OpenAI's effort to expand its AI capabilities beyond general use cases into professional applications requiring technical precision and accuracy.

Bloomberg L.P.
Apr 17th, 2026
OpenAI loses head of science initiatives and Sora AI video team leader

OpenAI's head of science initiatives and the leader of its Sora AI video team are leaving the company, adding to recent executive departures as the firm reorganises its product portfolio. The exits continue a pattern of senior leadership changes at the artificial intelligence company.

Bloomberg L.P.
Apr 16th, 2026
OpenAI unveils GPT-5.4 to tackle enterprise trust and governance concerns

OpenAI is addressing enterprise adoption challenges with GPT-5.4 "Cyber", focusing on security, trust and governance issues. Erica Brescia, managing director at Redpoint Ventures and OpenAI backer, discussed the development, emphasising that the AI cyber race centres on governance rather than purely technological advancement. The move represents OpenAI's effort to overcome barriers preventing widespread enterprise adoption of its AI systems by prioritising security features in its latest model release.

Bloomberg L.P.
Apr 16th, 2026
OpenAI launches GPT-Rosalind AI model for drug discovery to rival Google

OpenAI has launched GPT-Rosalind, an AI model designed to accelerate drug discovery and life sciences research. The model aims to extract insights from large datasets and help translate scientific studies into healthcare applications. Initially available as a research preview to select business customers, GPT-Rosalind's early users include pharmaceutical company Amgen, vaccine maker Moderna and bioscience research nonprofit the Allen Institute. The launch positions OpenAI alongside other technology companies entering the drug discovery field, as the industry seeks to demonstrate AI's potential for scientific breakthroughs. The ChatGPT maker announced the model's release on Thursday.